Psoriasis

DISCREET phase 3 research shows oral apremilast eases genital psoriasis symptoms, improving itch, clearance, and sexual quality of life through 32 weeks.

Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

Icotrokinra emerges as a groundbreaking oral treatment for moderate to severe psoriasis, showing superior efficacy compared with existing therapies at Maui Derm 2026.

Discover insights from the Horizons in Advanced Practice meeting on type 2 inflammation and psoriasis management.

Psoriasis impacts physical and emotional health, with hidden burdens like trauma and IPV affecting quality of life and care access.

The National Psoriasis Foundation (NPF) redefines psoriasis severity, emphasizing disease impact over extent, enhancing treatment access, and aligning clinical practice with patient needs.

Zasocitinib emerges as a highly selective and potent allosteric tyrosine kinase 2 (TYK2) inhibitor, showing promise for treating immune-mediated inflammatory diseases.

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

Explore how precision dermatology leverages immune pathways to enhance treatment for inflammatory skin diseases.

Envudeucitinib shows promising results as a new oral therapy for psoriasis, achieving high skin clearance rates and rapid symptom improvement in clinical trials.

Chronic skin diseases like psoriasis and AD are linked to high smoking and other addiction rates, highlighting the need for integrated psychosocial support.

Explore the latest French guidelines for systemic psoriasis therapy, highlighting new treatments and tailored management strategies for diverse patient needs.

Discover the latest advancements in psoriasis treatment, including innovative therapies and personalized care options for improved patient outcomes in 2025.

In part 3 of this Case-Based Roundtable supplement, experts discuss psoriatic therapies for hair-baring areas.

Omar Noor, MD, recently presented 3 cases of psoriasis in older patients at Horizons in Advanced Practice to discuss available treatment options and considerations for Medicare and in-office injections.

Zasocitinib emerges as a promising oral therapy for psoriasis, achieving significant skin clearance and favorable safety in recent phase 3 trials.

Soligenix reveals promising results from its phase 2a study of SGX302, a novel therapy for mild-to-moderate psoriasis, enhancing patient experience and efficacy.

Discover the latest breakthroughs in atopic dermatitis and psoriasis treatments for 2025, enhancing patient care and individualizing therapy options.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed psoriasis in high-impact sites, overall psoriatic disease, and available therapies.

In part 2 of this Case-Based Roundtable supplement, experts discuss therapeutic options for psoriasis when considering involvement of special areas.

In part 1 of this Case-Based Roundtable supplement, experts discuss biologic treatment options for psoriasis and balancing efficacy with patient needs.

The BLA is supported by phase 3 data demonstrating rapid skin clearance and sustained disease control in patients with GPP.

A meta-analysis of over 800,000 patients shows JAK inhibitors are generally as safe as TNF antagonists for various purposes.